Announcement • Jun 12
SEED Co.,Ltd. to Report Q1, 2027 Results on Aug 12, 2026 SEED Co.,Ltd. announced that they will report Q1, 2027 results on Aug 12, 2026 Reported Earnings • May 13
Full year 2026 earnings: EPS exceeds analyst expectations Full year 2026 results: EPS: JP¥37.50 (up from JP¥36.08 in FY 2025). Revenue: JP¥33.9b (up 2.1% from FY 2025). Net income: JP¥1.14b (up 3.9% from FY 2025). Profit margin: 3.3% (in line with FY 2025). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 10%. Revenue is forecast to grow 8.3% p.a. on average during the next 2 years, compared to a 6.4% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings. New Risk • May 12
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.1b (US$96.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (JP¥15.1b market cap, or US$96.0m). Announcement • May 11
SEED Co.,Ltd., Annual General Meeting, Jun 23, 2026 SEED Co.,Ltd., Annual General Meeting, Jun 23, 2026. Announcement • May 10
SEED Co.,Ltd. to Report Fiscal Year 2026 Results on May 11, 2026 SEED Co.,Ltd. announced that they will report fiscal year 2026 results on May 11, 2026 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 30 March 2026. Payment date: 25 June 2026. Payout ratio is a comfortable 39% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.2%). Valuation Update With 7 Day Price Move • Mar 13
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to JP¥625, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 17x in the Medical Equipment industry in Japan. Total returns to shareholders of 23% over the past three years. New Risk • Mar 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.7b (US$100.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Minor Risks Paying a dividend despite having no free cash flows. Market cap is less than US$100m (JP¥15.7b market cap, or US$100.0m). Reported Earnings • Feb 10
Third quarter 2026 earnings released: EPS: JP¥2.45 (vs JP¥9.15 in 3Q 2025) Third quarter 2026 results: EPS: JP¥2.45 (down from JP¥9.15 in 3Q 2025). Revenue: JP¥8.38b (flat on 3Q 2025). Net income: JP¥74.0m (down 73% from 3Q 2025). Profit margin: 0.9% (down from 3.3% in 3Q 2025). Revenue is forecast to grow 12% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has remained flat, which means it is significantly lagging earnings. Announcement • Dec 02
SEED Co.,Ltd. to Report Q3, 2026 Results on Feb 13, 2026 SEED Co.,Ltd. announced that they will report Q3, 2026 results on Feb 13, 2026 Reported Earnings • Nov 12
Second quarter 2026 earnings released: EPS: JP¥14.87 (vs JP¥6.25 in 2Q 2025) Second quarter 2026 results: EPS: JP¥14.87 (up from JP¥6.25 in 2Q 2025). Revenue: JP¥8.60b (flat on 2Q 2025). Net income: JP¥450.0m (up 138% from 2Q 2025). Profit margin: 5.2% (up from 2.2% in 2Q 2025). Revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 5.8% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 31% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Announcement • Sep 03
SEED Co.,Ltd. to Report Q2, 2026 Results on Nov 10, 2025 SEED Co.,Ltd. announced that they will report Q2, 2026 results on Nov 10, 2025 Reported Earnings • Aug 09
First quarter 2026 earnings released: EPS: JP¥12.59 (vs JP¥11.86 in 1Q 2025) First quarter 2026 results: EPS: JP¥12.59 (up from JP¥11.86 in 1Q 2025). Revenue: JP¥8.55b (up 3.3% from 1Q 2025). Net income: JP¥381.0m (up 6.1% from 1Q 2025). Profit margin: 4.5% (up from 4.3% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 9.5% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has fallen by 2% per year, which means it is significantly lagging earnings. Reported Earnings • Jun 27
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: JP¥36.08 (down from JP¥77.39 in FY 2024). Revenue: JP¥33.2b (up 2.6% from FY 2024). Net income: JP¥1.09b (down 44% from FY 2024). Profit margin: 3.3% (down from 6.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 46%. Revenue is forecast to grow 9.0% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Announcement • Jun 21
SEED Co.,Ltd. to Report Q1, 2026 Results on Aug 08, 2025 SEED Co.,Ltd. announced that they will report Q1, 2026 results on Aug 08, 2025 New Risk • May 15
New major risk - Financial position The company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 16% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risks Paying a dividend despite having no free cash flows. Profit margins are more than 30% lower than last year (3.3% net profit margin). Market cap is less than US$100m (JP¥13.9b market cap, or US$95.3m). Reported Earnings • May 13
Full year 2025 earnings: EPS exceeds analyst expectations Full year 2025 results: EPS: JP¥36.08 (down from JP¥77.39 in FY 2024). Revenue: JP¥33.2b (up 2.6% from FY 2024). Net income: JP¥1.09b (down 44% from FY 2024). Profit margin: 3.3% (down from 6.1% in FY 2024). The decrease in margin was driven by higher expenses. Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 46%. Revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 6.0% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to JP¥412, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 14x in the Medical Equipment industry in Japan. Total loss to shareholders of 13% over the past three years. Upcoming Dividend • Mar 21
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 28 March 2025. Payment date: 26 June 2025. Payout ratio is a comfortable 28% but the company is not cash flow positive. Trailing yield: 2.8%. Lower than top quartile of Japanese dividend payers (3.7%). Higher than average of industry peers (1.1%). Announcement • Mar 20
SEED Co.,Ltd. to Report Fiscal Year 2025 Results on May 12, 2025 SEED Co.,Ltd. announced that they will report fiscal year 2025 results at 3:00 PM, Tokyo Standard Time on May 12, 2025 Reported Earnings • Feb 08
Third quarter 2025 earnings released: EPS: JP¥9.15 (vs JP¥16.30 in 3Q 2024) Third quarter 2025 results: EPS: JP¥9.15 (down from JP¥16.30 in 3Q 2024). Revenue: JP¥8.36b (up 2.2% from 3Q 2024). Net income: JP¥277.0m (down 32% from 3Q 2024). Profit margin: 3.3% (down from 5.0% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.7% p.a. on average during the next 3 years, compared to a 7.0% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings. New Risk • Dec 24
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 6.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks High level of debt (63% net debt to equity). Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (6.6% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Valuation Update With 7 Day Price Move • Dec 24
Investor sentiment improves as stock rises 38% After last week's 38% share price gain to JP¥630, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 16x in the Medical Equipment industry in Japan. Total returns to shareholders of 23% over the past three years. Announcement • Dec 20
SEED Co.,Ltd. to Report Q3, 2025 Results on Feb 07, 2025 SEED Co.,Ltd. announced that they will report Q3, 2025 results on Feb 07, 2025 Buy Or Sell Opportunity • Dec 19
Now 21% overvalued The stock has been flat over the last 90 days, currently trading at JP¥511. The fair value is estimated to be JP¥424, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 5.0% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 18% in 2 years. Earnings are forecast to decline by 9.5% in the next 2 years. Reported Earnings • Nov 13
Second quarter 2025 earnings released: EPS: JP¥6.25 (vs JP¥15.98 in 2Q 2024) Second quarter 2025 results: EPS: JP¥6.25 (down from JP¥15.98 in 2Q 2024). Revenue: JP¥8.55b (up 7.0% from 2Q 2024). Net income: JP¥189.0m (down 53% from 2Q 2024). Profit margin: 2.2% (down from 5.0% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.6% p.a. on average during the next 3 years, compared to a 6.5% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 7% per year, which means it is significantly lagging earnings. New Risk • Oct 22
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥15.0b (US$99.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 3.8% per year for the foreseeable future. Minor Risks High level of debt (51% net debt to equity). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (JP¥15.0b market cap, or US$99.7m). Announcement • Sep 19
SEED Co.,Ltd. to Report Q2, 2025 Results on Nov 11, 2024 SEED Co.,Ltd. announced that they will report Q2, 2025 results on Nov 11, 2024 Reported Earnings • Aug 09
First quarter 2025 earnings released: EPS: JP¥11.86 (vs JP¥17.02 in 1Q 2024) First quarter 2025 results: EPS: JP¥11.86 (down from JP¥17.02 in 1Q 2024). Revenue: JP¥8.28b (up 4.1% from 1Q 2024). Net income: JP¥359.0m (down 16% from 1Q 2024). Profit margin: 4.3% (down from 5.4% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.8% p.a. on average during the next 3 years, compared to a 6.8% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 12% per year, which means it is performing significantly worse than earnings. New Risk • Aug 05
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: JP¥13.1b (US$92.0m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 6.1% per year for the foreseeable future. Minor Risks High level of debt (49% net debt to equity). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (JP¥13.1b market cap, or US$92.0m). Valuation Update With 7 Day Price Move • Aug 05
Investor sentiment deteriorates as stock falls 24% After last week's 24% share price decline to JP¥433, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 17x in the Medical Equipment industry in Japan. Total loss to shareholders of 34% over the past three years. Announcement • Jun 26
SEED Co.,Ltd. to Report Q1, 2025 Results on Aug 06, 2024 SEED Co.,Ltd. announced that they will report Q1, 2025 results on Aug 06, 2024 Reported Earnings • May 16
Full year 2024 earnings released: EPS: JP¥77.39 (vs JP¥12.62 loss in FY 2023) Full year 2024 results: EPS: JP¥77.39 (up from JP¥12.62 loss in FY 2023). Revenue: JP¥32.4b (up 5.9% from FY 2023). Net income: JP¥1.96b (up JP¥2.28b from FY 2023). Profit margin: 6.1% (up from net loss in FY 2023). The move to profitability was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings. Announcement • May 15
SEED Co.,Ltd., Annual General Meeting, Jun 25, 2024 SEED Co.,Ltd., Annual General Meeting, Jun 25, 2024. Announcement • Mar 26
SEED Co.,Ltd. has completed a Follow-on Equity Offering in the amount of ¥3.0849 billion. SEED Co.,Ltd. has completed a Follow-on Equity Offering in the amount of ¥3.0849 billion.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 4,550,000
Price\Range: ¥678
Discount Per Security: ¥31.64
Transaction Features: Subsequent Direct Listing Announcement • Mar 23
SEED Co.,Ltd. to Report Fiscal Year 2024 Results on May 13, 2024 SEED Co.,Ltd. announced that they will report fiscal year 2024 results on May 13, 2024 Upcoming Dividend • Mar 21
Upcoming dividend of JP¥15.00 per share Eligible shareholders must have bought the stock before 28 March 2024. Payment date: 28 June 2024. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Japanese dividend payers (3.2%). Higher than average of industry peers (0.9%). New Risk • Mar 07
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 18% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.7% per year over the past 5 years. Minor Risks High level of debt (87% net debt to equity). Large one-off items impacting financial results. Shareholders have been diluted in the past year (18% increase in shares outstanding). Announcement • Feb 21
SEED Co.,Ltd. has filed a Follow-on Equity Offering. SEED Co.,Ltd. has filed a Follow-on Equity Offering.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 4,550,000
Transaction Features: Subsequent Direct Listing Reported Earnings • Feb 09
Third quarter 2024 earnings released: EPS: JP¥16.30 (vs JP¥5.43 in 3Q 2023) Third quarter 2024 results: EPS: JP¥16.30 (up from JP¥5.43 in 3Q 2023). Revenue: JP¥8.18b (up 5.0% from 3Q 2023). Net income: JP¥408.0m (up 200% from 3Q 2023). Profit margin: 5.0% (up from 1.7% in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 33% per year but the company’s share price has increased by 6% per year, which means it is well ahead of earnings. Announcement • Dec 23
SEED Co.,Ltd. to Report Q3, 2024 Results on Feb 07, 2024 SEED Co.,Ltd. announced that they will report Q3, 2024 results on Feb 07, 2024 Reported Earnings • Nov 15
Second quarter 2024 earnings released: EPS: JP¥15.98 (vs JP¥2.04 loss in 2Q 2023) Second quarter 2024 results: EPS: JP¥15.98 (up from JP¥2.04 loss in 2Q 2023). Revenue: JP¥8.00b (up 9.3% from 2Q 2023). Net income: JP¥400.0m (up JP¥451.0m from 2Q 2023). Profit margin: 5.0% (up from net loss in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 18% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings. New Risk • Oct 10
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Earnings have declined by 7.9% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (5.2% average weekly change). New Risk • Sep 04
New major risk - Revenue and earnings growth Earnings have declined by 7.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Earnings have declined by 7.9% per year over the past 5 years. Announcement • Aug 30
SEED Co.,Ltd. to Report Q2, 2024 Results on Nov 10, 2023 SEED Co.,Ltd. announced that they will report Q2, 2024 results on Nov 10, 2023 Reported Earnings • Aug 10
First quarter 2024 earnings released: EPS: JP¥17.02 (vs JP¥7.35 in 1Q 2023) First quarter 2024 results: EPS: JP¥17.02 (up from JP¥7.35 in 1Q 2023). Revenue: JP¥7.95b (up 5.1% from 1Q 2023). Net income: JP¥426.0m (up 132% from 1Q 2023). Profit margin: 5.4% (up from 2.4% in 1Q 2023). Revenue is forecast to grow 8.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has fallen by 5% per year whereas the company’s share price has fallen by 2% per year. New Risk • Jun 19
New minor risk - Dividend sustainability The dividend is not well covered by earnings. The company is paying a dividend despite being loss-making. Dividend yield: 2.1% This is considered a minor risk. Companies that pay out too much of their earnings are at risk of having to reduce or cut their dividend in future. If earnings growth slows or earnings fall, then there may not be enough earnings to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. However, this risk is mitigated by the fact the dividend is covered by cash flows. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risks Paying a dividend despite being loss-making. Market cap is less than US$100m (JP¥13.8b market cap, or US$97.5m). Announcement • Jun 11
SEED Co.,Ltd. to Report Q1, 2024 Results on Aug 09, 2023 SEED Co.,Ltd. announced that they will report Q1, 2024 results on Aug 09, 2023 Reported Earnings • May 17
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: JP¥12.62 loss per share (down from JP¥46.06 profit in FY 2022). Revenue: JP¥30.6b (up 6.1% from FY 2022). Net loss: JP¥316.0m (down 127% from profit in FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates. Revenue is forecast to grow 8.1% p.a. on average during the next 2 years, compared to a 5.9% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings. Announcement • May 14
SEED Co.,Ltd., Annual General Meeting, Jun 27, 2023 SEED Co.,Ltd., Annual General Meeting, Jun 27, 2023. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥12.00 per share at 2.2% yield Eligible shareholders must have bought the stock before 30 March 2023. Payment date: 27 June 2023. Payout ratio is a comfortable 37% and this is well supported by cash flows. Trailing yield: 2.2%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.1%). Reported Earnings • Feb 14
Third quarter 2023 earnings released: EPS: JP¥5.43 (vs JP¥13.42 in 3Q 2022) Third quarter 2023 results: EPS: JP¥5.43 (down from JP¥13.42 in 3Q 2022). Revenue: JP¥7.79b (up 5.9% from 3Q 2022). Net income: JP¥136.0m (down 60% from 3Q 2022). Profit margin: 1.7% (down from 4.6% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 17% per year, which means it is significantly lagging earnings. Announcement • Nov 30
SEED Co.,Ltd. to Report Q3, 2023 Results on Feb 13, 2023 SEED Co.,Ltd. announced that they will report Q3, 2023 results on Feb 13, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: JP¥2.04 loss per share (vs JP¥5.19 profit in 2Q 2022) Second quarter 2023 results: JP¥2.04 loss per share (down from JP¥5.19 profit in 2Q 2022). Revenue: JP¥7.32b (flat on 2Q 2022). Net loss: JP¥51.0m (down 139% from profit in 2Q 2022). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.3% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 22% per year, which means it is significantly lagging earnings. Board Change • Nov 16
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. Independent Outside Director Yukio Obara was the last independent director to join the board, commencing their role in 2015. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 13
Second quarter 2023 earnings released: JP¥2.04 loss per share (vs JP¥5.19 profit in 2Q 2022) Second quarter 2023 results: JP¥2.04 loss per share (down from JP¥5.19 profit in 2Q 2022). Revenue: JP¥7.32b (flat on 2Q 2022). Net loss: JP¥51.0m (down 139% from profit in 2Q 2022). Revenue is forecast to grow 6.5% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Medical Equipment industry in Japan. Over the last 3 years on average, earnings per share has increased by 34% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings. Announcement • Aug 31
SEED Co.,Ltd. to Report Q2, 2023 Results on Nov 11, 2022 SEED Co.,Ltd. announced that they will report Q2, 2023 results on Nov 11, 2022 Reported Earnings • Aug 09
First quarter 2023 earnings released: EPS: JP¥7.35 (vs JP¥5.63 in 1Q 2022) First quarter 2023 results: EPS: JP¥7.35 (up from JP¥5.63 in 1Q 2022). Revenue: JP¥7.57b (up 12% from 1Q 2022). Net income: JP¥184.0m (up 31% from 1Q 2022). Profit margin: 2.4% (up from 2.1% in 1Q 2022). Over the next year, revenue is forecast to grow 5.0%, compared to a 9.4% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 35% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings. Announcement • Jun 01
SEED Co.,Ltd. to Report Q1, 2023 Results on Aug 08, 2022 SEED Co.,Ltd. announced that they will report Q1, 2023 results on Aug 08, 2022 Announcement • May 12
SEED Co.,Ltd., Annual General Meeting, Jun 24, 2022 SEED Co.,Ltd., Annual General Meeting, Jun 24, 2022. Reported Earnings • May 11
Full year 2022 earnings: EPS exceeds analyst expectations Full year 2022 results: EPS: JP¥46.06 (up from JP¥45.10 in FY 2021). Revenue: JP¥28.8b (flat on FY 2021). Net income: JP¥1.15b (up 2.1% from FY 2021). Profit margin: 4.0% (up from 3.9% in FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 117%. Over the next year, revenue is forecast to grow 4.7%, compared to a 7.9% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. 2 independent directors (6 non-independent directors). External Auditor Shunji Tanefusa was the last director to join the board, commencing their role in 2010. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Announcement • Apr 08
SEED Co.,Ltd. to Report Fiscal Year 2022 Results on May 10, 2022 SEED Co.,Ltd. announced that they will report fiscal year 2022 results on May 10, 2022 Upcoming Dividend • Mar 23
Upcoming dividend of JP¥12.00 per share Eligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 32% and this is well supported by cash flows. Trailing yield: 2.3%. Lower than top quartile of Japanese dividend payers (3.4%). Higher than average of industry peers (0.9%). Reported Earnings • Feb 12
Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind Third quarter 2022 results: EPS: JP¥13.42 (down from JP¥23.69 in 3Q 2021). Revenue: JP¥7.36b (down 5.1% from 3Q 2021). Net income: JP¥336.0m (down 43% from 3Q 2021). Profit margin: 4.6% (down from 7.6% in 3Q 2021). Revenue missed analyst estimates by 4.7%. Earnings per share (EPS) exceeded analyst estimates by 13%. Over the next year, revenue is forecast to grow 7.2%, compared to a 7.3% growth forecast for the industry in Japan. Over the last 3 years on average, earnings per share has increased by 9% per year but the company’s share price has fallen by 24% per year, which means it is significantly lagging earnings. Reported Earnings • Nov 15
Second quarter 2022 earnings released: EPS JP¥5.19 (vs JP¥8.87 in 2Q 2021) The company reported a poor second quarter result with weaker earnings and profit margins, although revenues were flat. Second quarter 2022 results: Revenue: JP¥7.29b (flat on 2Q 2021). Net income: JP¥130.0m (down 41% from 2Q 2021). Profit margin: 1.8% (down from 3.0% in 2Q 2021). Over the last 3 years on average, earnings per share has remained flat but the company’s share price has fallen by 29% per year, which means it is significantly lagging earnings. Reported Earnings • Aug 11
First quarter 2022 earnings released: EPS JP¥5.63 (vs JP¥1.12 loss in 1Q 2021) The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥6.73b (up 10% from 1Q 2021). Net income: JP¥141.0m (up JP¥169.0m from 1Q 2021). Profit margin: 2.1% (up from net loss in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 15% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings. Reported Earnings • May 15
Full year 2021 earnings released: EPS JP¥45.10 (vs JP¥10.07 in FY 2020) The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥28.6b (down 10.0% from FY 2020). Net income: JP¥1.13b (up 348% from FY 2020). Profit margin: 3.9% (up from 0.8% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 36% per year whereas the company’s share price has fallen by 32% per year. Upcoming Dividend • Mar 23
Upcoming dividend of JP¥12.00 per share Eligible shareholders must have bought the stock before 30 March 2021. Payment date: 26 June 2021. Trailing yield: 1.6%. Lower than top quartile of Japanese dividend payers (2.7%). Higher than average of industry peers (0.7%). Announcement • Mar 04
SEED Co.,Ltd. to Report Fiscal Year 2021 Results on May 12, 2021 SEED Co.,Ltd. announced that they will report fiscal year 2021 results on May 12, 2021 Is New 90 Day High Low • Feb 25
New 90-day high: JP¥660 The company is up 10.0% from its price of JP¥598 on 27 November 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Medical Equipment industry, which is flat over the same period. Reported Earnings • Feb 07
Third quarter 2021 earnings released: EPS JP¥23.69 (vs JP¥5.71 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: JP¥7.76b (up 6.6% from 3Q 2020). Net income: JP¥593.0m (up 315% from 3Q 2020). Profit margin: 7.6% (up from 2.0% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has only fallen by 30% per year, which means it has not declined as severely as earnings. Analyst Estimate Surprise Post Earnings • Feb 07
Revenue beats expectations, earnings disappoint Revenue exceeded analyst estimates by 5.4%. Earnings per share (EPS) missed analyst estimates by 70%. Over the next year, revenue is forecast to grow 5.0%, compared to a 6.9% growth forecast for the Medical Equipment industry in Japan. Announcement • Sep 21
SEED Co.,Ltd.(TSE:7743) dropped from S&P Global BMI Index SEED Co.,Ltd.(TSE:7743) dropped from S&P Global BMI Index